## CITATION REPORT List of articles citing

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

DOI: 10.1200/jco.2005.04.8678 Journal of Clinical Oncology, 2006, 24, 190-205.

**Source:** https://exaly.com/paper-pdf/41009455/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF | Citations |
|-----|--|----|-----------|
| 103 | 5Reductase Inhibitors and Chemoprevention: The PCPT and Beyond. <b>2006</b> , 5, 746-751   |    | 2         |
| 102 | Evaluation of lung MDCT nodule annotation across radiologists and methods. 2006, 13, 1254-65   |    | 60        |
| 101 | Cyclin A activity predicts clinical outcome in oral precancer and cancer. <b>2006</b> , 35, 1041-6   |    | 14        |
| 100 | The Clinical Management of Neuropathic Pain. <b>2006</b> , 11, 30A-36A   |    | 2         |
| 99  | Genomic signatures to guide the use of chemotherapeutics. <b>2006</b> , 12, 1294-300   |    | 494       |
| 98  | Surgical management of cancer of the colon. <b>2006</b> , 38, 124-128  |    | 1         |
| 97  | [Future of chemotherapy]. <b>2006</b> , 45, 567-71   |    | O         |
| 96  | [Chemotherapy registry quality in Andalusian hospital pharmacy departments]. 2006, 30, 370-3   |    | 2         |
| 95  | Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. <b>2006</b> , 98, 1134-41   |    | 185       |
| 94  | Altered bone and mineral metabolism in patients receiving imatinib mesylate. <b>2006</b> , 354, 2006-13  |    | 248       |
| 93  | Quality of life for patients with epithelial ovarian cancer. <b>2007</b> , 4, 18-29  |    | 45        |
| 92  | Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. <b>2007</b> , 10, 388-95                           |    | 25        |
| 91  | Minimally invasive anterior thoracotomy for routine lung cancer resection. <b>2007</b> , 2, 76-83  |    | 6         |
| 90  | Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. <b>2007</b> , 18, 745-51         |    | 51        |
| 89  | Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. <b>2007</b> , 67, 1487-93 |    | 36        |
| 88  | Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. <b>2007</b> , 18, 477-85    |    | 66        |
| 87  | Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. <b>2007</b> , 42, 791-6  |    | 21        |

## (2008-2007)

| 86 | Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. 2007, 356, 323-8   | 295 |
|----|---|-----|
| 85 | Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. <b>2007</b> , 8, 177-8   | 118 |
| 84 | Opioid analgesics in the management of neuropathic pain. <b>2007</b> , 1, 57-60   | 2   |
| 83 | Targeted therapies for soft-tissue sarcomas. <b>2007</b> , 7, 725-33  | 5   |
| 82 | Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancera review of the literature. <b>2007</b> , 12, 201-10   | 69  |
| 81 | Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer. <b>2007</b> , 7, 837-44   | 6   |
| 80 | [Causes of lung cancer: smoking, environmental tobacco smoke exposure, occupational and environmental exposures and genetic predisposition]. <b>2007</b> , 128, 390-6                                     | 13  |
| 79 | Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. <b>2007</b> , 67, 333-50  | 84  |
| 78 | Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. <b>2007</b> , 110, 660-9                               | 143 |
| 77 | Community attitudes towards the early detection of cancer in Victoria, Australia. <b>2007</b> , 31, 26-29   | 6   |
| 76 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. <b>2008</b> , 26, 81-7 | 142 |
| 75 | Long term physical sequelae after adult-onset cancer. <b>2008</b> , 2, 3-11   | 51  |
| 74 | Implementation of a comprehensive cancer plan. A health planning experience. 2008, 10, 213-8  |     |
| 73 | Toward the individualization of lung cancer therapy. <b>2008</b> , 113, 1760-7  | 16  |
| 72 | Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IVa feasibility study. <b>2008</b> , 18, 1114-22  | 60  |
| 71 | The TRAIL apoptotic pathway in cancer onset, progression and therapy. <b>2008</b> , 8, 782-98   | 690 |
| 7º | Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. <b>2008</b> , 31, 359-71  | 29  |
| 69 | Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. <b>2008</b> , 10, 521-33   | 77  |

| 68   | Utilization of genomic signatures to direct use of primary chemotherapy. <b>2008</b> , 18, 62-7   | 23   |
|--|---|--|
| 67   | Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. <b>2008</b> , 14, 3427-33  | 45   |
| 66   | Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act. <b>2008</b> , 51, 377-406  | 29   |
| 65   | A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. <b>2008</b> , 3, 590-8  | 44   |
| 64   | An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. <b>2008</b> , 3, e1908  | 71   |
| 63   | [Development of a system for extracting the information of candidate tumor markers reported in biomedical literatures]. <b>2008</b> , 28, 79-87   |  |
| 62   | Utilization of genomic signatures to identify phenotype-specific drugs. 2009, 4, e6772  | 19   |
| 61   | Targeting death-receptors in radiation therapy. <b>2009</b> , 49, 219-39  | 8  |
| 60   | Cardio-oncology: a new medical issue. <b>2008</b> , 2, 126  | 16   |
|  |   |  |
| 59   | Cell death in hematological tumors. <b>2009</b> , 14, 409-23  | 37   |
| 59<br>58   | Cell death in hematological tumors. <b>2009</b> , 14, 409-23  Is TRAIL the holy grail of cancer therapy?. <b>2009</b> , 14, 607-23  | 107  |
|  |   |  |
| 58   | Is TRAIL the holy grail of cancer therapy?. <b>2009</b> , 14, 607-23  | 107  |
| 58<br>57   | Is TRAIL the holy grail of cancer therapy?. <b>2009</b> , 14, 607-23  Programmed cell death pathways and current antitumor targets. <b>2009</b> , 26, 1547-60   | 107<br>114   |
| 58<br>57<br>56   | Is TRAIL the holy grail of cancer therapy?. 2009, 14, 607-23  Programmed cell death pathways and current antitumor targets. 2009, 26, 1547-60  Follow-up care for cancer survivors: the views of clinicians. 2009, 101, 568-74  | 107<br>114<br>54                                       |
| <ul><li>58</li><li>57</li><li>56</li><li>55</li></ul>            | Is TRAIL the holy grail of cancer therapy?. 2009, 14, 607-23  Programmed cell death pathways and current antitumor targets. 2009, 26, 1547-60  Follow-up care for cancer survivors: the views of clinicians. 2009, 101, 568-74  Psychogenic carcinogenesis: carcinogenesis is without exogenic carcinogens. 2009, 73, 531-6   | 107<br>114<br>54                                       |
| <ul><li>58</li><li>57</li><li>56</li><li>55</li><li>54</li></ul> | Is TRAIL the holy grail of cancer therapy?. 2009, 14, 607-23  Programmed cell death pathways and current antitumor targets. 2009, 26, 1547-60  Follow-up care for cancer survivors: the views of clinicians. 2009, 101, 568-74  Psychogenic carcinogenesis: carcinogenesis is without exogenic carcinogens. 2009, 73, 531-6  Apoptosis in Cancer Biology and Cancer Therapeutics. 2009, 581-596  Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in | <ul><li>107</li><li>114</li><li>54</li><li>5</li></ul> |

## (2013-2010)

| 50 | Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors. <b>2010</b> , 116, 3195-204  |     | 69  |
|----|--|-----|-----|
| 49 | Authorship and industry financial relationships: the tie that binds. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1281-3  | 2.2 | 2   |
| 48 | Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1527-33 | 2.2 | 187 |
| 47 | Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <b>2010</b> , 21, 195-198   |     | 28  |
| 46 | Targeted therapies in cancer. <b>2010</b> , 24, 77-88  |     | 29  |
| 45 | Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. <b>2010</b> , 1, e68   |     | 51  |
| 44 | Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. <b>2011</b> , 21, 32-41   |     |     |
| 43 | Treatment and prevention of cardiotoxicity due to anticancer therapy. <b>2011</b> , 21, 92-100   |     | 1   |
| 42 | Molekular zielgerichtete Tumortherapie durch Eingriffe in die zellul <b>ß</b> e Signaltransduktion. <b>2011</b> , 17, 520-527  |     |     |
| 41 | Role of biomarkers in cardioncology. <b>2011</b> , 49, 1937-48   |     | 32  |
| 40 | Combined modality therapy with TRAIL or agonistic death receptor antibodies. <b>2011</b> , 11, 431-49  |     | 36  |
| 39 | Long-term health-related quality of life in survivors of head and neck cancer. <b>2012</b> , 138, 123-33   |     | 128 |
| 38 | WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. 2012, 10, 75-85   |     | 26  |
| 37 | Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. <b>2012</b> , 7, e31070  |     | 39  |
| 36 | Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). <b>2012</b> , 4, 201-8  |     | 6   |
| 35 | State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. <b>2013</b> , 88, 75-86  |     | 51  |
| 34 | Kardionkologia [bdpowied[ha wyzwania wspldzesnej terapii. <b>2013</b> , 10, 11-23  |     |     |
| 33 | The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care. <b>2013</b> , 20,  |     |     |

| 32 | Using cardiac biomarkers and treating cardiotoxicity in cancer. <b>2013</b> , 9, 105-18  | 20  |
|----|--|-----|
| 31 | Subclinical ventricular dysfunction detected by speckle tracking two years after use of anthracycline. <b>2015</b> , 104, 274-83   | 4   |
| 30 | TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. <b>2014</b> , 74, 385-91   | 11  |
| 29 | Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. <b>2014</b> , 134, 1695-705  | 31  |
| 28 | Cancer patientsTand professional caregiversTneeds, preferences and factors associated with receiving and providing fertility-related information: a mixed-methods systematic review. <b>2014</b> , 51, 300-19  | 76  |
| 27 | Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma. <b>2015</b> , 4, 2719-26  | 57  |
| 26 | Effects of pediatric cancer and its treatment on nutritional status: a systematic review. <b>2015</b> , 73, 276-95   | 36  |
| 25 | Communication difficulties and the experience of loneliness in patients with cancer dealing with fertility issues: a qualitative study. <b>2015</b> , 42, 34-43  | 14  |
| 24 | Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. <b>2015</b> , 1, 88-96 | 207 |
| 23 | New Frontiers in Cancer Chemotherapy Targeting Cell Death Pathways. 2016,  | 5   |
| 22 | 5-Hydroxyvitamin D concentration in paediatric cancer patients from Scotland: a prospective cohort study. <b>2016</b> , 116, 1926-1934   | 8   |
| 21 | Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. <b>2016</b> , 7, 11311   | 23  |
| 20 | Systematic review and meta-analysis: Prevalence and possible causes of vitamin D deficiency and insufficiency in pediatric cancer patients. <b>2016</b> , 35, 95-108   | 17  |
| 19 | Antihistamines as promising drugs in cancer therapy. <b>2017</b> , 172, 27-41  | 32  |
| 18 | 2D longitudinal LV speckle tracking strain pattern in breast cancer survivors: sports activity vs exercise as prescription model. <b>2017</b> , 12, 1149-1157  | 5   |
| 17 | Renal thrombotic microangiopathy caused by bevacizumab. <b>2018</b> , 23, 378-379  | 1   |
| 16 | Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir. 2018, 23, 379-380  | 2   |
| 15 | Barriers and facilitators towards fertility preservation care for cancer patients: a meta-synthesis. <b>2018</b> , 27, e12428  | 37  |

## CITATION REPORT

| 14 | A narrative synthesis of the quality of cancer care and development of an integrated conceptual framework. <b>2018</b> , 27, e12881  | 10 |
|----|--|----|
| 13 | Detection of Multiple Breast Cancer ESR1 Mutations on an ISFET Based Lab-on-Chip Platform. <b>2021</b> , 15, 380-389   | 9  |
| 12 | Minimally Invasive Anterior Thoracotomy for Routine Lung Cancer Resection. 2007, 2, 76-83  | 1  |
| 11 | A framework for the organization and delivery of systemic treatment. <b>2009</b> , 16, 4-15  | 12 |
| 10 | Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate. <b>2007</b> , 13, 5765-70  | 2  |
| 9  | Pathogenesis of Cancer: Cancer Reparative Trap. <b>2015</b> , 06, 399-412  | 9  |
| 8  | Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. <b>2011</b> , 2, 367-76   | 31 |
| 7  | The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care. <b>2013</b> , 20, e57-8  |    |
| 6  | Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients. <b>2021</b> , 22, 3355-3363   |    |
| 5  | Community attitudes towards the early detection of cancer in Victoria, Australia. <b>2007</b> , 31, 26-29  | О  |
| 4  | Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. 2008, 8, 137-48   | 5  |
| 3  | Cell Culture-Based Assessment of Toxicity and Therapeutics of Phytochemical Antioxidants  Molecules, <b>2022</b> , 27,  4.8  | 1  |
| 2  | Promoting symptom research in cooperative groups. 237-246  |    |
| 1  | Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab. <i>Internal Medicine</i> , <b>2022</b> , | O  |